chadv63.hivconsv
Vaccineexperimental
Clinical trial activity
4 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2010 (NCT01151319)
Timeline
Indications
Studied for
Mechanism of action
- Human immunodeficiency virus type I enhancer-binding protein 1Immunity, active
HIVEP1 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- chadv63.hivconsv
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02336074 | Phase 2 | Nov 27, 2015 | Medical Research Council, University of Cambridge, University of London, University of Oxford, University of Sussex |
| NCT02425241 | Phase 1/Phase 2 (Phase 2) | Oct 1, 2013 | GlaxoSmithKline, Medical Research Council, University of London, University of Oxford |
| NCT01712425 | Phase 1 | Oct 1, 2012 | Fundacio Lluita Contra la SIDA, HIVACAT, Institut de Recerca de la Sida IrsiCaixa-HIVACAT, IrsiCaixa, University of Barcelona, University of Oxford |
| NCT01151319 | Phase 1 | Oct 1, 2010 | University of Oxford |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Oxford | Academic/Hospital | 4 | 1 | 2 | 2010 |
| Medical Research Council | Government | 2 | 0 | 1 | 2013 |
| University of London | Academic/Hospital | 2 | 2 | 1 | 2013 |
| Fundacio Lluita Contra la SIDA | Academic/Hospital | 1 | 0 | 1 | 2012 |
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2013 |
| HIVACAT | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Institut de Recerca de la Sida IrsiCaixa-HIVACAT | Academic/Hospital | 1 | 0 | 1 | 2012 |
| IrsiCaixa | Academic/Hospital | 1 | 1 | 1 | 2012 |
| University of Barcelona | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Cambridge | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Sussex | Academic/Hospital | 1 | 0 | 1 | 2015 |
11 organizations
Page 1 / 1